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Summary
It is paramount that any child or adolescent with a suspected
disorder of sex development (DSD) is assessed by an experi-
enced clinician with adequate knowledge about the range of
conditions associated with DSD. If there is any doubt, the case
should be discussed with the regional DSD team. In most cases,
particularly in the case of the newborn, the paediatric endocri-
nologist within the regional team acts commonly as the first
point of contact. This clinician should be part of a multidisci-
plinary team experienced in management of DSD and should
ensure that the affected person and parents have access to spe-
cialist psychological support and that their information needs
are comprehensively addressed. The underlying pathophysiology
of DSD and the strengths and weaknesses of the tests that can
be performed should be discussed with the parents and affected
young person and tests undertaken in a timely fashion. Finally,
in the field of rare conditions, it is imperative that the clinician
shares the experience with others through national and interna-
tional clinical and research collaboration.
(Received 21 April 2015; returned for revision 18 June 2015;
accepted 11 July 2015)
Introduction and development of guidance
Disorders of sex development (DSD) are a wide range of condi-
tions with diverse features and pathophysiology1 that most often
present in the newborn or the adolescent. Affected newborns
usually present with atypical genitalia, whereas adolescents pre-
sent with atypical sexual development during the pubertal years.
These clinical situations can often be difficult to manage, partic-
ularly in those cases where the sex of rearing is uncertain. Devel-
oping a logical and pragmatic plan for investigations whilst
establishing a dialogue and building rapport with the affected
child and the parents is central to the initial approach and
ongoing management.
The consensus reached in Chicago in 2005 on the general
principles of managing patients with DSD represented a historic
milestone for international and multidisciplinary collaboration
in this area.2,3 Some areas of care, such as the initial approach
to evaluating the infant or young person with suspected DSD,
were not covered in detail as that was beyond the scope of the
exercise. As guidance on the initial evaluation of a complex con-
dition is often coloured by local provision of health care, it was
felt in 2009 that reaching a consensus at a national, UK level
was the most effective means of proceeding further. A UK DSD
taskforce was formed in March that year under the auspices of
the UK Society for Endocrinology, and it was agreed that the
remit of this group would be to concentrate on guidance on the
initial evaluation process and the diagnostic approach rather
than the clinical management of the condition once a provi-
sional or definitive diagnosis has been reached.4 This guidance
would be aimed at a range of clinical professionals who encounter
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newborns and adolescents with DSD, and its purpose would not
be simply to act as a manual but to harmonize good clinical
practice. Stakeholder professional societies and clinical profes-
sionals who could represent these societies were identified and
approached to join the taskforce, as were members of two
patient support/advocacy groups (Appendix 1). These taskforce
members took responsibility for individual sections and based
their opinion on observational studies and expert opinion, and
the whole taskforce considered each draft. After completion, the
guidelines were subject to open external review by the involved
professional societies and their members as well as patient group
representatives. After this period of open consultation of over
3 months, comments were reviewed and most suggestions were
incorporated. All members of the taskforce approved the final
draft of the guidance that was first published in 2011.4 This revi-
sion of the guidance which was initiated in 2014 has taken a
similar path as described above.
The multidisciplinary team
Optimal care for infants and adolescents with DSD requires an
experienced multidisciplinary team (MDT) that should be acces-
sible through regional centres. The team may exist as a clinical
network with links between more than one specialist centre. As
a minimum standard, the clinical team should include specialists
in endocrinology, surgery and/or urology, clinical psychology/
psychiatry, radiology, nursing and neonatology. Ideally, discus-
sions with the family are led by one professional. In most situa-
tions, particularly in the case of the newborn, the paediatric
endocrinologist assumes the role of clinical lead and oversees the
timely involvement of other members of the team. Other team
members should be discouraged from providing results as soon
as they are received. For infants with suspected DSD, this team
should develop a plan for clinical management with respect to
diagnosis, sex assignment and management options. The lead
clinician should process this information, co-ordinate further
support and take responsibility for sharing the information with
the parents so that informed decisions can be reached in a
timely manner. The process of informing parents, children and
young people of the various investigations and results should be
documented such that the whole MDT team is aware of the
status of new or ongoing conversations with the family. In addi-
tion, the clinical team should have links to a wider MDT which
consists of specialists from adult endocrinology, plastic surgery,
gynaecology, clinical genetics, clinical biochemistry, adult clinical
psychology and social work and, if possible, to a clinical ethics
forum5 (Table 1). However, the core composition of the team
for each affected person and family will vary according to DSD
type, family need or preference, local resources, developmental
context and location as well as the age of the person. The par-
ents and the young person should be informed of the range of
support that is available from the MDT and should be provided
with contact details of these personnel. Ongoing communication
with the family’s primary care physician is important, and
consent issues in relation to sharing information outside of the
hospital setting should be discussed with parents and young per-
son. The team has a responsibility to educate other healthcare
staff and should have a forum to meet regularly, in the context
of a clinic and an educational meeting where the team can
review and discuss its own performance. Audit of clinical activ-
ity, research studies, building collaborative working partnerships
with other DSD teams and attendance at joint clinics and educa-
tion events are crucial if knowledge and information sharing are
to be optimized across MDT teams. Transfer of care for the
adolescent should be organized with the multidisciplinary team
operating in an environment comprising specialists with experi-
ence in adolescent care.6
Psychological support for the affected person and
family
Early psychological input, provided by a specialist clinical psy-
chologist with experience of supporting people with DSD and
their parents, will allow those affected to examine and under-
stand their early emotional reactions as well as explore present
and future worries, adjust to the period of uncertainty during
the diagnosis process and facilitate inclusion in informed deci-
sion-making about themselves or their child.7–11 The clinical
psychologist is also well placed to assess the level of support the
family needs, assess and facilitate the bonding of the parents
with the newborn and, in the case of the young person, perform
an assessment of gender identity, when appropriate. As a mini-
mum, the parents of every newborn with suspected DSD where
there has been a delay in sex assignment should be offered clini-
cal psychology input. In addition, all adolescents with a newly
diagnosed DSD or existing DSD requiring medical or surgical
attention should be routinely offered clinical psychology input
in addition to any support offered to their parents or wider
family. The point of transfer from paediatric to adult services
offers an ideal opportunity for a standardized assessment of the
need for future clinical psychology input.
Discussions with parents and young people need to occur on
multiple occasions in a quiet and peaceful setting, with enough
time for the family and MDT to develop a shared understanding
of investigations, results, diagnosis, management and the value
of ongoing psychological support for both themselves and/or
their child. The pace at which information is shared should be
set by the family, and issues of confidentiality should be dis-
cussed and respected.12 Parents’ and young people’s initial recol-
lections of conversations with professionals may have long-
lasting effects on them and their relationship with their child
and health professionals.13 The use of phrases such as ‘differ-
ences’ or ‘variations’ in sex development may help to introduce
the concept of the range of variation that may occur in sex
development. The acronym, DSD, lends itself to be used as a
phrase that includes ‘differences and disorders of sex develop-
ment’ and, as such, may be more acceptable to the young person
and their parents.14 The team should be cognizant of the needs
of the parents who cannot speak English fluently. It is also pos-
sible that for rare dialects and languages, the interpreter may
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originate from the same community. A record of early discus-
sions, either as audiotapes or as a letter, which is shared between
the parents and other immediate members of the MDT and the
general practitioner may be helpful. Use of drawings and written
material during discussion and a list of websites and support
groups are useful aids for families.
Parents and young people need to be aware that the manage-
ment of the condition will require a step-wise approach that first
targets short-term goals and then more distant goals that achieve
optimal long-term well-being.15 It is very likely that families’
decisions will be shaped by their own expectations, experiences,
and their understanding of sex and gender roles within the reli-
gious and cultural context of their own social networks. Some
parents may consider early genital surgery as a mechanism that
could possibly protect their child from the risk of future
stigma.16 This will require a thorough discussion with several
members of the MDT team including the clinical psychologist,
surgeons, gynaecologist and nurses so that the parents are fully
Table 1. The clinical members of the MDT and their roles in providing care to the patient and the parents.
Role
Neonatologist or General Paediatrician Initial explanation
Management of the unwell child
Initiation of first-line investigations
Seek advice from paediatric subspecialist (endocrine or surgical) with an interest in DSD
Paediatric Endocrinologist* Detailed explanation over multiple visits
Management of the unwell child
Interpreting first-line investigations and planning second-line investigations
Organize timely and appropriate involvement of other members of MDT
Act as the link between the parents and MDT
Initiate and monitor long-term medical therapy such as steroid or sex steroid therapy
Paediatric Radiologist Interpret and often perform ultrasound scans in the newborn
Judge the reliability of ultrasound scans in the newborn esp. when the results may influence sex assignment
Paediatric Urologist* Assessment of external anatomy
Explanation of the anatomy and results of imaging
Explanation of pros and cons of reconstructive surgery
Develop a plan for complex imaging (other than pelvic ultrasound) and further assessment of the anatomy
Perform procedures such as laparoscopy, biopsy, reconstructive surgery and gonadectomy
Organize timely and appropriate involvement of other members of MDT
Paediatric Specialist Nurse* Provide general support to the patient and parents in addition to that provided by other members of the MDT
Arrange specialist investigations
Liaise with the rest of the DSD team, including the clinical psychologist
Clinical Psychologist* Provide specialist support to parents soon after birth
Provide support to the growing up child and the parents
Develop an individualized plan for each family
Guide the MDT on timing and tempo of explanation of the condition to the older child and adolescent
Clinical Endocrine Biochemist* Facilitate timely analysis of samples
Provide specialist support and interpretation of results
Guide subsequent biochemical tests
Facilitate storage of samples for analysis at a later stage
Clinical Geneticist* Facilitate timely analysis of karyotype
Closer involvement in the child with dysmorphic features
Oversee the process of genetic analysis
Facilitate storage of samples for analysis at a later stage
Genetic counselling
Gynaecologist* Availability at an early stage to discuss future outcome and map long-term care pathway in the affected girl
Discuss issues related to sexual function, reproductive function and surgery
Assess the understanding and review the diagnosis
Assess the need for psychology support in the adolescent girl
Initiate and monitor long-term sex steroid therapy
Perform examination, investigative and therapeutic procedures in the adolescent girl
Oversee vaginal dilator training with specialist nurse
Adult Endocrinologist Investigate and manage the adolescent presenting for the first time after the age of 16 years
Liaise with other members of the MDT
Act as the link between the patient and MDT
Initiate and monitor long-term medical therapy such as steroid or sex steroid therapy
Act as the transition link for adolescents under paediatric care
*Professionals that are core members of the MDT who should meet regularly to discuss cases in a clinic setting.
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informed of the controversies around undertaking or withhold-
ing early genital surgery.17,18 Parents and young people will need
support and guidance about how to share news following the
birth of their child/diagnosis and manage the social challenges
they may face at this time.12,19 Members of the MDT should
also be aware of how their own values and beliefs are played out
in consultation with the family.
The role of the support group
Support groups can provide ongoing support to parents and the
affected individual, including opportunities to gather and explore
information, promote autonomy, and build knowledge and self-
confidence regarding the diagnosis of DSD. For parents, gather-
ing, using and questioning information will shape their under-
standing as they often act as the advocate for their child or young
person and therefore need to be fully informed about DSD prac-
tice, short and long-term outcomes of treatments, and health risks
and psychological challenges for their child. Support groups can
provide a range of such information via websites and newsletters
as well as through phone helplines and group meetings for both
families and professionals.13,20 They can also work in collabora-
tion with the MDT to help families as well as affected people in
seeking appropriate medical care and improve patients’ under-
standing of their condition as well as the reasons for medical ther-
apy.7 Alongside the formal psychological support provided by the
specialist clinical psychologist, support groups can also offer
invaluable peer support to families and individuals affected by
DSD. By being in touch with others with a similar condition and
belonging to a support group, people can gain a sense of empow-
erment and the whole experience may also normalize a condition
that may have previously been perceived as a source of stigma.21
Healthcare professionals rely on support groups for guidance on
the development of healthcare strategy as well as for providing the
opportunity to interact with affected people at national support
group meetings and conferences.22 Contact details of national
support groups and web resources such as AIS Support Group
(aissg.org), CAH Support Group (livingwithcah.com) and dsd-
families.org should be supplied as routine as part of any written
information. Whilst such groups and resources are not subject to
a standard process of national accreditation in the UK, the co-in-
volvement of local clinical experts as advisors has allowed these
groups to function within the framework of clinical practice in
the UK. However, it is also possible that families may prefer to
talk to local families affected in a similar way and the remit of
regional services should include the creation of a local pool of
helpers and locally organized support and education days. Some
parents may not wish to access support groups or meet other fam-
ilies, and the members of the MDT should also be aware and over
time review these wishes.
Which newborn should be investigated and how
extensively?
It is generally accepted that investigations are necessary in those
cases where the appearance of the genitalia is so ambiguous that
sex assignment is not possible at birth or the appearance is not
consistent with any prenatal genetic tests. However, the extent of
genital ambiguity may depend on the expertise of the observer
and prior to presentation to a clinical expert, the label of am-
biguous genitalia is often assigned to newborns where the most
appropriate sex of rearing is not immediately clear to those pre-
sent at the child’s birth. The birth prevalence of atypical geni-
talia may be as high as 1 in 300 births,23 but the birth
prevalence of a condition that may lead to true genital ambigu-
ity on expert examination may be as low as 1 in 5000 births.24
Besides those whose genitalia are truly ambiguous, in the clin-
ical situation, infants can often be divided into those who are
apparently a boy with atypical genitalia and those who are
apparently a girl with atypical genitalia. However, it is very
important to bear in mind that the same girl with congenital
adrenal hyperplasia may present as an apparent girl with cli-
toromegaly or an apparent boy with bilateral undescended testes.
When evaluating these infants, the clinical features of the exter-
nal genitalia that require examination include the presence of
gonads in the labioscrotal folds, the fusion of the labioscrotal
folds, the size of the phallus and the site of the urinary meatus
on the phallus, although the real site of the urinary meatus may,
sometimes, only become clear on surgical exploration.25 These
external features can be individually scored to provide an aggre-
gate score, the external masculinization score (EMS)26 (Fig. 1).
Routine systematic examination of 423 consecutive, apparently
healthy, term newborn boys revealed that 412 (98%) had the
maximum EMS of 12, 10 had an EMS of 11 and only 1 of 423
had an EMS of less than 11.26 In boys with atypical genitalia, a
chromosomal anomaly may be present in approximately 3% of
those with isolated cryptorchidism, 7% of those with hypospa-
dias and 13% of those with a combination of cryptorchidism
and hypospadias.27 In infants with proximal hypospadias (peno-
scrotal, scrotal, perineal), detailed biochemical and molecular
studies performed over a decade ago revealed a likely cause in
about 30% of cases28 and based on current reports of genetic
analysis in XY DSD, a genetic cause may be identified in about
40% of cases.29 With advances in biochemical and molecular
techniques, it is unclear whether the diagnostic yield is even
greater now.
Infants with suspected DSD who require further clinical evalu-
ation and need to be considered for investigation by a specialist
should include those with isolated perineal hypospadias, isolated
micropenis, isolated clitoromegaly, any form of familial
hypospadias and those who have a combination of genital
anomalies with an EMS of less than 11. This will avoid unneces-
sary detailed investigations of boys with isolated glandular or
mid-shaft hypospadias and boys with unilateral inguinal testis.
In approximately 25% of affected cases, DSD is part of a com-
plex condition30 and the coexistence of a systemic metabolic dis-
order, other malformations or dysmorphic features, would lower
the threshold for investigation as would a family history of con-
sanguinity, stillbirths, multiple miscarriages, fertility problems,
genital abnormalities, hernias, delayed puberty, genital surgery,
unexplained deaths and the need for steroid replacement. In
addition, maternal health and drug exposure during pregnancy
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and the pregnancy history itself may hold key information.
Knowledge of birthweight in XY DSD is very helpful and as
highlighted by a recent report that showed a lower yield of
mutations in AR in those cases who had a lower birthweight for
gestation.31
In all infants with ambiguous genitalia and/or bilateral impal-
pable gonads, a first tier of investigations should be undertaken
to define the sex chromosomes and delineate, by pelvic ultra-
sound, the internal genitalia and exclude life-threatening con-
genital adrenal hyperplasia (CAH) – the commonest cause of
ambiguous genitalia of the newborn. This first tier should, there-
fore, also include plasma glucose, serum 17OH-progesterone
(17OHP) and serum electrolytes. Serum 17OHP is usually unre-
liable before the age of 36 h, and in the salt-losing form of
CAH, serum electrolytes usually do not become abnormal before
day 4 of life. The results of PCR or FISH analysis using Y- and
X-specific markers should be available within one working day,
and the 17OHP results should be available with a maximum of
two working days in all specialist DSD centres. In situations
where the level of suspicion of CAH is very high and the infant
needs immediate steroid replacement therapy, further serum
samples should be collected and stored before starting therapy.
These should be of a sufficient volume to assess 17OHP, testos-
terone, androstenedione and, possibly, renin activity or concen-
tration, in that order of priority. At least one spot or 24-h urine
sample (at least 5 ml) for a urine steroid profile should be
collected before starting therapy. The results of these initial
investigations shall often dictate the second tier of investigations.
In an infant with impalpable gonads, a karyotype of 46,XX, a
significantly elevated serum 17OHP and the presence of a uterus
makes congenital adrenal hyperplasia (CAH) due to 21-hydroxy-
lase deficiency very likely. A urine steroid profile can confirm
this diagnosis and can also identify other rare forms of CAH,
which may also be associated with a raised 17OHP in the new-
born such as 11b-hydroxylase deficiency and 3b-hydroxysteroid
dehydrogenase deficiency. In infants with sex chromosomes
other than 46,XX, a second tier of investigations is necessary to
determine the presence of testes and the adequacy of androgen
production and action. These tests include measurement of
serum anti-M€ullerian hormone (AMH), the hCG stimulation
test, urinalysis for proteinuria, further detailed imaging and
laparoscopy. Confirmation of a specific diagnosis will often
require further biochemical identification of a defect in the
androgen biosynthesis pathway and detailed genetic analysis.
Which adolescent should be investigated and how
extensively?
The initial assessment in an affected adolescent should not only
start the process of diagnosis but should also be used to develop
a rapport with the patient. In adolescents with an existing DSD,
transferring to adult services is an opportunity to review the
diagnosis and consider further investigations. An appropriate
hospital setting is very important for the sensitive management
of complex conditions with full access to the necessary medical,
nursing and psychological care. Whilst the explanation of the
diagnosis to the patient and the family is critical, this needs to
be performed sensitively and carefully and expert psychological
input is essential over a period of time.
Adolescents may typically present with a suspected DSD in
three ways – a girl with primary amenorrhoea (with or without
breast development), a girl who virilizes at puberty or a boy
with pubertal delay (Fig. 2). The potential psychological impact
of examinations and medical photography should be considered
and for the adolescent, a thorough physical examination by a
surgeon and a gynaecologist, depending on the sex of the adoles-
cent, may only be appropriate under an anaesthetic.32
In girls with primary amenorrhoea, investigations should be
considered at the age of 14 years if there is no pubertal develop-
ment and at 16 years if other aspects of puberty, particularly
breast development, have progressed normally. History should
include a family history and an assessment of coexisting chronic
disease, exercise and weight changes. Physical examination
should include measurement of blood pressure, height and
weight and assessment of secondary sexual characteristics includ-
ing clitoral enlargement. Vaginal examination to assess vaginal
length is rarely indicated if imaging is informative and should
be clearly explained and performed by a gynaecologist. An initial
investigation screen should comprise measurements of serum
electrolytes, LH, FSH, prolactin, TSH, FT4, SHBG, androstene-
dione, oestradiol, testosterone and transabdominal pelvic ultra-
sound by a sonographer who has experience of ultrasonography
in children/adolescents and is aware of normative data. Raised
gonadotrophins or an absent uterus in the presence of normal
breast development is the indication for a karyotype.
The appearance of clitoromegaly and hirsutism at puberty in
the presence of primary amenorrhoea is a classical presentation
of two 46,XY DSDs: 17b-hydroxysteroid dehydrogenase type 3
deficiency and 5a-reductase type 2 deficiency. It is less typical
of partial androgen insensitivity syndrome (PAIS) which is usu-
ally associated with ambiguous genitalia at birth. In all these
conditions, M€ullerian structures will not be detectable. Also, in
partial gonadal dysgenesis, alterations in steroidogenic factor-1
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(SF-1/NR5A1) and ovotesticular DSD, the mild clitoromegaly
that may have been present at birth, may have been overlooked
but becomes a more prominent feature at adolescence. The dif-
ferential diagnosis would also include congenital adrenal hyper-
plasia and androgen-secreting tumours of the ovary or adrenal
gland; in all these cases, M€ullerian structures are present. Investi-
gations include serum measurements of LH, FSH, DHEAS,
SHBG, androstenedione, testosterone, dihydrotestosterone and
17OHP. A 24-h urine collection for urinary steroid profile will
confirm 5a-reductase type 2 deficiency, CAH or adrenocortical
tumour. A pelvic ultrasound will assess the presence of a uterus
and determine the need for a karyotype.
Although the commonest cause of delayed puberty is constitu-
tional delay, all boys with delayed puberty who are over the age
of 14 years should be assessed. Overweight boys need careful
examination so that a buried penis is not mistaken for micrope-
nis. Rarely, PAIS, a disorder of testosterone biosynthesis or mild
forms of testicular dysgenesis, can present in this age group,
especially if there is a history of hypospadias repair or orchi-
dopexy. Investigations include a bone age and serum measure-
ments of LH, FSH, testosterone and prolactin. For those with
raised gonadotrophins, karyotype should be performed to
exclude disorders such as Klinefelter’s syndrome (47,XXY and
variants) or 45,X/46,XY mosaicism.
The role of the clinical geneticist
Establishing a specific molecular diagnosis is helpful in the clini-
cal management of cases and in offering accurate genetic coun-
selling for the family. In those cases, where a clear steroidogenic
defect has been identified biochemically, targetted single-gene
analysis will confirm the diagnosis in most cases. However, in
46,XY DSD with no clear abnormality of steroidogenesis, the
yield from diagnostic genetic testing has often been poor,
costly and limited, with less than 50% of affected cases having
an identified genetic alteration. With the advent of genomic medi-
cine, the ability to better diagnose, predict and treat disease is
anticipated to transform many aspects of care.32 For individuals
with a DSD, its utility may reside in ending diagnostic uncertainty.
Vast improvements in genetic sequencing technology com-
bined with a huge reduction in costs has provided a stimulus
for change, with next-generation sequencing and whole-genome-
and-exome sequencing (WGES) becoming available in clinical
practice (Fig 3).33 Diagnostic DNA laboratories are moving from
single-gene sequencing (sequential analysis) to next-generation
sequencing assays (parallel testing), designed to sequence multi-
ple DSDs genes on a targeted panel in one analysis or whole-ex-
ome sequencing with predetermined filters that target DSD
genes.29 A targeted panel is advantageous as it yields high-quality
coverage of the genes of interest, whilst minimizing the risk of
incidental findings. For example, a panel of thirty-two 46, XX
DSD and 46, XY DSD genes (to complement CYP21A2 testing)
with a turnaround time of 80 days has been developed in one
UK Genetic Regional Laboratory.34 Currently, most targeted
panels interrogate 5–200 genes, in comparison to the 3000
known genes currently covered by whole-exome sequencing.35
The clinical geneticist at the specialist DSD centre can evaluate
complex genetic syndromes and advise which genetic testing
technique is appropriate and cost-effective for each clinical situa-
tion, once urgent karyotype testing and copy number variant
analysis have been completed (Fig 3).36 With the advent of tar-
geted panels and WGES, more extensive biochemical and radio-
logical investigations might be reserved until answers from
analysis are obtained, with the potential to avoid further costly
investigations.29 However, there are challenges in bringing
WGES into routine practise, which is expected to become main-
stream in the next 5 years.37 Pretest counselling needs to be
broader, to cover all potential test outcomes, whilst explaining
the limitations of this approach. In addition, in line with inter-
national recommendations, patients and parents should be
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Genetic Evaluation of DSD
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identified
Cascade genetic 
testing in the family
No abnormalities found-
MDT review
Fig. 3 Role of the clinical genetics service within the specialist DSD team. MLPA, mutation ligation-dependent probe amplification; CGH, comparative
genomic hybridisation.
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informed about the possibility of unsolicited findings of medi-
cally relevant disease variants.38 It is, therefore, recommended
that procedures such as WGES should only currently be consid-
ered following informed consent and as part of an ethics
approved study.
Close involvement of the clinical genetics service can ensure
that the MDT covers all aspects of genetic counselling including
provision of information to the family, the mode of inheritance
of the disorder and the choices or options available for dealing
with this risk. Established links with the clinical genetics service
are also useful when considering prenatal testing or interven-
tions such as steroid therapy in CAH (Fig. 3). As the scope for
prenatal noninvasive diagnosis using free-floating foetal DNA
becomes more realistic, the close involvement of the clinical
geneticist at a very early stage in at-risk pregnancies will become
even more important.39
Assessment of anatomy
Examination and assessment by a paediatric surgeon with expe-
rience of DSD is critically important in the affected newborn.
Combining expert physical examination with endoscopic visual-
ization and radiological assessment can provide information on
the location and state of the gonads, the urogenital sinus and
M€ullerian structures. During this initial assessment, the anatomy
and drainage of the renal tract should also be assessed.40,41
Ultrasonography is the first-line imaging modality and
includes analysis in the adrenals, kidneys, pelvis, inguinal regions
and scrotum where appropriate. In the neonate, the uterus,
ovaries and adrenals should be easily identifiable, but the relia-
bility is child and operator dependent. It should also be borne
in mind that the presence of a uterine structure does not guar-
antee later function and intra-abdominal testes and streak
gonads are difficult to identify ultrasonography. In the adoles-
cent, it is sometimes difficult to confirm the presence of a pre-
pubertal uterus by ultrasonography and there may be a place for
repeat imaging after a 6-month course of oestrogen. Magnetic
resonance imaging (MRI) should be reserved for cases where
ultrasonography has failed to delineate the relationship of the
M€ullerian structures and where there are abnormalities of the
urinary tract. High-resolution MRI should include the pelvis
and perineum and use high-resolution T2 with and without fat
saturation and T1 in three planes where possible. MRI can iden-
tify extra-abdominal ectopic testes and the presence of the sper-
matic cords, but is of less value in trying to define the presence
and character of intra-abdominal testes or streak gonads. In
adolescents, MRI can delineate structural anomalies such as
hydrometrocolpos or hydronephrosis and identify secretory
tumours, but its value in identifying premalignant changes in
retained testes remains questionable.42 In general, T1 imaging of
the upper abdomen in adolescents is not required unless there is
an adrenal mass in which case contrast enhancement shall also
be required.43,44
Nowadays, the ‘genitogram’ is not routinely performed for
diagnostic purposes. It has been superseded by endoscopic
examination of the genital tract (genitoscopy), which provides a
more detailed and thorough assessment. However, at the time of
surgery, stents can be accurately placed in various structures to
allow a more focused radiological examination. These investiga-
tions need to provide information on the length of the urogeni-
tal sinus, the associated M€ullerian structures and the
relationship of the urethra and its sphincter. In 46,XX DSD,
genitoscopy can assess drainage of both the bladder and M€ulle-
rian structures and provide a detailed assessment of the urogeni-
tal anatomy. In 46,XY DSD, endoscopic examination can be
used to identify any M€ullerian remnants that arise from the
posterior urethra.
Genitoscopy can be augmented by laparosocopy, but this is
not necessary in all cases of DSD. It is a very effective method
of visualizing the internal sex organs and facilitates direct
inspection, biopsy or excision of intra-abdominal gonads. How-
ever, as laparoscopy can only visualize intraperitoneal structures,
M€ullerian remnants deep within the pelvis or closely attached to
the bladder may not be seen. In 46,XY DSD, laparoscopy is
clearly indicated in all infants with impalpable testes where the
gonads need to be identified and brought down to the scrotum
if possible. Laparoscopy can also be used in adolescents who
present with a DSD. However, MRI may be a more suitable
first-line investigation for defining the anatomy. It should be
borne in mind that it is possible that in the absence of prior
oestrogen exposure, a uterus may be difficult to identify on
ultrasound, MRI and even laparoscopy and in a case of raised
suspicion, a trial of oestrogen therapy would be advisable.
Steroid measurement and its interpretation
Steroid hormone analysis is a vital component of the biochemi-
cal evaluation, but the method of analysis can have a significant
impact on the result.45 Analysis is most often performed by
nonextraction or nonchromatographic (direct) immunoassays
on automated platforms, and these are subject to concerns of
analytical specificity.46,47 Liquid chromatography linked with
tandem mass spectrometry (LC-MS/MS) allows multiple analyte
analysis from a single sample whilst maintaining analytical speci-
ficity.48 Thus, in cases of DSD, plasma or serum steroids should
be measured by either LC-MS/MS or immunoassays after
organic solvent extraction. As these are more labour intensive,
there may be an impact on the turnaround time for results and
on clinical decision-making. Close communication between the
clinical and biochemistry personnel within the DSD team is vital
to enable correct interpretation of laboratory results and aware-
ness that results should be available in a timely manner.
Urinary steroid profile (USP) analysis by gas chromatography
mass spectrometry (GC-MS) provides qualitative and quantita-
tive data on excretion of steroid metabolites. It is ideal for
detecting altered steroid metabolites, especially in cases of CAH
where the activity of a combination of steroidogenic enzymes
can produce unusual metabolites, which can cross-react in tradi-
tional serum assays.49 The diagnosis of rarer forms of CAH such
as P450 oxidoreductase deficiency (PORD) is best established
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using urinary GC-MS analysis as it allows for concurrent deter-
mination of all adrenal-derived steroid metabolites.50,51 As gona-
dotrophins, androgens and precursors fluctuate markedly over
the first few months of life and may lead to a diagnostically
blind window, there is a place to consider an early neonatal col-
lection as well as further samples at a later stage. A urine sample
can be frozen and stored for many years and may help with a
review of the diagnosis at a later stage. USP is not appropriate
for suspected cases of 5a-reductase type 2 deficiency until after
3 months of age as diagnostic pairs of 5b-to 5a-reduced
metabolites are not detectable until then.
Normally, infants, particularly, boys, have significant changes
in steroid and other endocrine hormone concentrations during
the first 100 days of birth.46,52 In boys, serum testosterone and
DHT may initially be high at birth but decline to less than
1 nmol/l or undetectable, respectively. Concentrations then rise
from around day 30 after birth to peak at day 70 before declin-
ing to normal prepubertal concentrations.51 These normal varia-
tions may influence the interpretation of sex steroid and
gonadotrophin measurements as well as the results of the hCG
stimulation test. Furthermore, the actual value for the hormone
concentration will vary depending on the assay methodology.
Serum Anti-M€ullerian Hormone (AMH)
AMH, also known as M€ullerian inhibiting substance (MIS), is
strongly expressed in Sertoli cells from the time of testicular dif-
ferentiation to puberty and to a much lesser degree in granulosa
cells from birth to menopause and is widely used nowadays to
assess ovarian reserve.53 Published information on circulating
AMH concentrations have to be interpreted with caution due to
differences in the way immunoassays are standardized and the
units used for measurement. It is therefore important to liaise
with the specialist clinical biochemist to ensure appropriate ref-
erence ranges are used for interpretation. In boys, AMH is
detectable at birth at a much higher circulating concentrations
than in girls and these concentrations rise over infancy before
gradually declining at puberty. Therefore, up to date, age, sex
and method-related reference ranges are necessary for interpreta-
tion.54 In male neonates, levels that are close to the lower end of
the normal range should be repeated later in infancy as they
should rise further in boys with normal testes. As summarized
in Table 2, measurement of AMH is a powerful tool to assess
Sertoli cell activity in children with suspected DSD and may also
have a diagnostic utility in conditions associated with androgen
deficiency or insensitivity 54,55 (Table 2). The discriminant value
of AMH value in cases of bilateral anorhcia is so high that an
undetectable AMH in such a case may avoid the need for inva-
sive surgical exploration.56
The human chorionic gonadotrophin (hCG)
stimulation test
Stimulation with hCG allows the identification of functioning
testicular tissue as well as biosynthetic defects in testosterone
synthesis (Fig. 4). However, it is an invasive test that should
only be performed as a second-line investigation after discussion
with the paediatric endocrinologist in the regional DSD team.
Most protocols for hCG stimulation in the UK use intramuscu-
lar hCG 1000–1500 units on three consecutive days.57 This can
be followed by further hCG stimulation with 1500 units on
2 days per week for the following 2 weeks. In young infants and
adolescents, 3 days of hCG stimulation may be sufficient,58 and
in the very young infant with an intrinsically active gonadal axis,
an hCG stimulation test may not be necessary if serial blood
samples show raised serum testosterone concentrations. A testos-
terone response to hCG may be labelled as normal if absolute
testosterone concentrations reach a level that is above the upper
limit of the normal prepubertal range, or rise by more than
twice the baseline value.55,57–59 As a minimum, other androgens
that should be assessed include dihydrotestosterone (DHT) and
androstenedione. For these two metabolites, the post-hCG, day
4 sample is more important than the pre-hCG sample on day 1.
If there are sufficient samples to analyse on day 4, there does
not seem to be any additional benefit of analysing a sample for
these two metabolites on day 22.58 The day 22 sample that is
collected for testosterone measurement should be stored and can
be used to measure DHT or androstenedione if a sufficient sam-
ple was not available at day 4.
In routine cases of XY DSD, a persistently low AMH may
have a high predictive value for a low hCG-stimulated testos-
terone concentration, but a normal AMH has a low predictive
value for a normal hCG-stimulated testosterone value.54 These
relationships between the two variables do not apply to cases of
Table 2. Interpretation of serum AMH concentration in DSD
Serum AMH
Testicular
tissue Interpretation
Undetectable or
very low
Absent 46,XX CAH
Complete gonadal dysgenesis
PMDS due to AMH gene
defect
Congenital anorchia
Within female
age-related
reference range
Usually absent 46,XX CAH
Complete gonadal dysgenesis
Dysgenetic testes or ovotestes
Below male or above
female age-related
reference range
Present Dysgenetic testes
Ovotestes
Within male age-related
reference range
Usually normal Non-specific XY,DSD
Hypogonadotrophic
hypogonadism
PMDS due to AMH-R
defect
46,XX testicular DSD
Ovotestes
Above male age-related
reference range
Present AIS esp. CAIS
5a-reductase deficiency
Testosterone biosynthetic
defect
Leydig cell hypoplasia
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persistent M€ullerian duct syndrome where there is an intrinsic
defect of AMH or the AMH receptor. There is no evidence that
a urine steroid profile or a serum AMH checked after hCG stim-
ulation has any added diagnostic value. In the presence of a
poor testosterone response following hCG stimulation, assess-
ment of adrenal function by a standard short Synacthen stimula-
tion test should be considered in all cases. There is less
experience as well as a lower demand for a corresponding test to
assess ovarian tissue, but recent reports of ovarian hormones fol-
lowing stimulation with FSH need to be explored further.60,61
There is currently insufficient evidence to recommend that
everybody with XY DSD should have a Synacthen stimulation
test, but clinicians should be aware of the clear association
between some forms of DSD and primary adrenal insufficiency
and should consider thorough assessment of adrenal function in
those diagnoses where an association has already been described
and in those with any clinical suspicion of adrenal insufficiency,
especially those with low steroid precursors on USP.
XX DSD
46,XX DSD can be classified into disorders of ovarian develop-
ment, conditions with androgen excess and other syndromes,
which are often associated with other developmental abnormali-
ties.
Congenital adrenal hyperplasia (CAH) is the commonest
cause of 46,XX DSD with ambiguous genitalia in the neonatal
period or early infancy and is characterized by androgen excess
and a variable alteration in glucocorticoid and mineralocorticoid
function and a specific profile of steroid hormones.62,63 This
profile can identify the enzyme defects including deficiency of
21a-hydroxylase (90–95% of cases), 11b-hydroxylase (4–8% of
cases), 3b-hydroxysteroid dehydrogenase type 2 (rare) and P450
oxidoreductase (unknown prevalence). P450 oxidoreductase
deficiency (PORD) biochemically manifests as apparent
combined CYP17A1 and CYP21A2 deficiency, sometimes also
resembling CYP19A1 (aromatase) deficiency. Unlike other forms
of CAH, PORD is characterized by increased androgen concen-
trations only during the prenatal and early neonatal period, but
rapidly develop sex hormone deficiency. Further details of these
enzyme defects are outlined in Table 3.
46,XX DSD also includes disorders of gonadal development
including 46,XX ovotesticular DSD and 46,XX testicular DSD.
46,XX ovotesticular DSD commonly presents at birth with
ambiguous genitalia and progressive virilization during puberty.
In contrast, individuals with 46,XX testicular DSD usually have
a male phenotype and absent M€ullerian structures and are often
diagnosed after karyotype analysis during work-up for infertility.
In 46,XX testicular DSD, about 80–90% of patients will have Y
chromosomal material including a translocated SRY gene, which
is only rarely detected in 46,XX ovotesticular DSD. In other
cases of 46,XX testicular DSD, duplications of the SOX9 gene
and mutations of the RSPO1 gene have been described. In those
with a suspicion of 46,XX ovotesticular DSD, functional testing
will require detection of testicular and ovarian tissue by a com-
bination of biochemical testing, imaging and surgical explo-
ration.
Disorders of M€ullerian development are another group of 46,
XX DSD and in these cases, ovarian function is usually normal
but often associated with cloacal anomalies and other character-
istic malformations. Although most cases of M€ullerian develop-
ment disorders are not associated with androgen excess, the
presence of the latter, particularly in the adolescent, should alert
the clinician to a possible abnormality of the WNT4 gene.
XY DSD with low testosterone and low precursors
The differential diagnosis of 46,XY DSD associated with low
testosterone and low precursors includes: high defects in steroid
synthesis (steroidogenic acute regulatory (StAR) protein, P450
Low T & 
Low Precursors
Low T & 
High Precursors
High T, Low DHT
High Ur 5β:5α
High/Normal/Low T
Normal DHT
Normal /High AMH
Poor functional response to T
LHR 
Gon 
dysg
SF-1
StAR
P450scc
SF-1
CYP17A1
POR
HSD3B2
SRD5A2 AR
Standard HCG stimulation
ACTH stimulated Cortisol Response**
CYP17A1 def
POR def
HSD3B2 def
HSD17B3 def
Prolonged HCG 
stimulation*
Low T & 
Low Precursors
Normal Low Normal Low
HSD17B3 
Fig. 4 Interpretation of the results of the hCG
stimulation test when investigating XY DSD and
pointers for consideration of prolonged hCG
stimulation and ACTH stimulation. Prolonged
hCG stimulation test should be considered in those
cases where there is a poor testosterone response to
a standard hCG stimulation test. Synacthen
stimulation test should be considered in those cases
who show a poor testosterone response to hCG
stimulation. 46,XY children with lipoid CAH due
to a StAR defect or P450scc deficiency due to
CYP11A1 defect will have female genitalia and
present in a salt-losing state in the first days or
weeks of life before Synacthen performed.
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side chain cleavage(scc) enzyme/CYP11A1, sometimes Smith-
Lemli-Optiz/DHCR7); LH receptor defects (LHCGR); and partial
and complete forms of gonadal (testicular) dysgenesis (Table 4).
Of note, complete or partial combined 17a-hydroxylase/17,20-
lyase deficiency (CYP17A1) may also present with ‘low testos-
terone and low precursors’ if DHEAS and androstenedione are
the only intermediates measured. The actual diagnosis can be
reached by the assessment of adrenal function by measuring
ACTH, ACTH-stimulated cortisol, PRA, DOC, corticosterone,
aldosterone, measurement of D5 (pregnenolone, 17OHPreg) and
D4 (progesterone, 17OHP) precursors or urine steroid analysis.
Isolated 17,20-lyase deficiency, cytochrome b5 deficiency and
PORD might also be diagnosed by this approach. Proximal
blocks (StAR, P450scc) in the pathway affect steroidogenesis in
the adrenal gland as well as the developing gonad.
LH receptor defects (‘Leydig cell hypoplasia’) typically result
in elevated basal LH, hyperresponsive LH to GnRH stimulation,
low precursors and testosterone, and impaired androgen
response to hCG stimulation. No M€ullerian structures will
be present, and adrenal function is normal. A spectrum of
phenotypes has been reported including ambiguous genitalia
and micropenis. In some cases, basal LH may not be elevated
at times when the HPG axis is quiescent (6 months to late
childhood).
In complete gonadal dysgenesis (‘Swyer syndrome’), affected
people will usually have a female phenotype with intra-abdomi-
nal streak gonads and a risk of tumour development.2 In some
situations, ovotestes or even undifferentiated gonadal tissue may
be found.64–66 M€ullerian structures are usually present due to
impaired AMH secretion in early foetal life. Androgens and their
precursors will be low, LH elevated, depending on age, and a
poor or absent testosterone response to hCG stimulation is seen.
AMH concentrations will be low or undetectable, and adrenal
function is usually normal unless the underlying defect is in
steroidogenic factor-1 (NR5A1) or related adrenal or gonadal
factors.
Partial gonadal (testicular) dysgenesis can present with a spec-
trum of phenotypes ranging from clitoromegaly, to ambiguous
genitalia or severe hypospadias. M€ullerian structures may or
may not be present, and testes of variable size and architecture
Table 3. Characteristics of 46, XX DSD due to androgen excess
Inheritance
and Gene Genitalia
Wolffian
duct
derivatives
Mullerian
duct
derivatives Gonads Typical signs and symptoms Hormone profile
21-hydroxylase
def
Autosomal
Recessive,
CYP21A2
Ambiguous Absent Normal Ovary Severe adrenal insufficiency
in infancy  salt loss;
moderate to severe
androgenization at birth
Decreased cortisol and/or
mineralocorticoids.
Increased
17-hydroxyprogesterone,
21-deoxycortisol,
androstenedione, testosterone,
and/or plasma renin (activity)
11b-hydroxylase
def
Autosomal
Recessive,
CYP11B1
Ambiguous Absent Normal Ovary Adrenal insufficiency in
infancy; moderate to severe
androgenization at birth;
arterial hypertension often
developing at different ages
Decreased cortisol,
corticosterone, aldosterone,
and or plasma renin (activity)
Increased 11-deoxycortisol,
11-deoxycorticosterone,
androstenedione, testosterone
3b-hydroxysteroid
dehydrogenase
II def
Autosomal
Recessive,
HSD3B2
Commonly
clitoromegaly
or mild
virilization can
also be normal
Absent Normal Ovary Severe adrenal insufficiency
in infancy  salt loss,
androgenization during
childhood and puberty,
premature pubarche
Increased concentrations of D5
C21- and C19- steroids, 17
hydroxypregnenolone and
DHEA suppressible by
dexamethasone
P450
oxidoreductase
def
Autosomal
Recessive,
POR
Ambiguous or
normal female
Absent Normal Ovary Variable androgenization at
birth and puberty,
glucocorticoid deficiency,
features of skeletal
malformations.
Maternal androgenization
during pregnancy onset
second trimester possible
Combined P450c17 and
P450c21 insuff, normal or low
cortisol with poor response to
ACTH stim, elevated
17-hydroxyprogesterone,
testosterone, progesterone and
corticosterone; low oestradiol.
P450 aromatase
def
Autosomal
Recessive,
CYP19A1
Ambiguous Absent Normal Ovary Delayed bone age,
development
of ovarian cysts
during infancy,
childhood and puberty.
Maternal androgenization
during pregnancy
High androgens in cord blood,
androgens may stay elevated or
normalize soon after birth
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are present along the path of descent. The biochemical profile is
similar to complete gonadal dysgenesis, but generally less severe.
If mild degrees of clitoromegaly in infancy are overlooked, a 46,
XY child with partial gonadal dysgenesis may first present at
puberty with progressive androgenization. Genetic analysis and
associated features may be useful in defining the molecular aeti-
ology of some forms of gonadal dysgenesis.67 This group of con-
ditions are also associated with a risk of tumour development,
which may be related to the extent of androgenization of the
external genitalia in the XY child.68
XY DSD with low testosterone and high steroid
precursors
46,XY DSD with low testosterone and increased precursors can
be caused by several variants of CAH, namely by 17a-hydroxy-
lase (CYP17A1) deficiency, PORD and 3b-hydroxysteroid dehy-
drogenase type 2 (3bHSD2) deficiency, caused by inactivating
mutations in the corresponding genes CYP17A1, POR and
HSD3B2, respectively. In addition, 46,XY DSD with low testos-
terone and increased precursors can typically be found in indi-
viduals affected by 17b-hydroxysteroid dehydrogenase type 3
(17bHSD3) deficiency, caused by HSD17B3 mutations
(Table 4).
Deficiency of CYP17A1 leads to CAH in about 1% of cases of
46,XY DSD. Characteristically, affected individuals present with
a female genitalia and low DHEA, androstenedione and testos-
terone. There is an increase in mineralocorticoid synthesis, and
although there may be cortisol deficiency, this is rarely mani-
fested, as corticosterone can also bind and activate the glucocor-
ticoid receptor. In PORD, sex steroids are characteristically low,
sometimes low normal, while pregnenolone and progesterone
and their metabolites accumulate, as expression of the combined
block of CYP21A2 and CYP17A1 activities. Although there is
often a relative preponderance of mineralocorticoid over gluco-
corticoid metabolites in affected cases, hypertension only mani-
fests in adolescence or later. Although baseline glucocorticoid
secretion is usually sufficient, in the majority of cases, the stress
response to ACTH is significantly impaired, requiring at least
stress dose hydrocortisone cover or permanent glucocorticoid
replacement. 3b-HSD2 (also termed D4-D5 isomerase) deficiency
invariably leads to glucocorticoid deficiency as well as a variable
degree of mineralocorticoid deficiency, and its characteristic fea-
tures are outlined in Table 4. 17b-HSD3 deficiency is responsi-
ble for the conversion of androstenedione to testosterone in the
gonad and has no effect on adrenal steroidogenesis. Plasma ster-
oids characteristically show increased androstenedione levels,
while testosterone levels are concurrently low, particularly after
hCG stimulation. However, a low testosterone to androstene-
dione ratio may also occur in cases of gonadal dysgenesis and
the reliability of a low ratio in identifying 17b-HSD3 deficiency
is unclear. In urine, the typical finding is an increase in the
androgen (and androstenedione) metabolites, androsterone (An)
and etiocholanolone (Et), but it is unclear whether this applies
across all age groups.49
XY DSD with normal testosterone, normal precursors
and low DHT
The type 2 isoenzyme of 5a-reductase type 2 (SRD5A2) is highly
expressed in androgen-sensitive tissues69 and converts testos-
terone to the more potent androgen, dihydrotestosterone (DHT)
required for the development of external male genitalia. At birth,
the external appearance of the genitalia of an infant with
SRD5A2 deficiency can range from a completely female pheno-
type to a range of hypospadias severity or, rarely, isolated
micropenis. A positive family history is often present in this
autosomal recessive condition. In serum, the testosterone:DHT
ratio following hCG stimulation often exceeds 30:1, but there
are several reports of cases with a lower ratio.70 In infants over
3–6 months, the defect should be easily identifiable simply on a
urine sample, which shows a decreased ratio for 5a:5b-reduced
C21 and C19 steroids and thus can be reached in a child who
had early gonadectomy. Early diagnosis of this condition is
important as the affected infant may need sex reassignment if
initially raised as a girl, and definitive diagnosis in a highly sus-
picious case may require access to a diagnostic genetics service
with a quick turnaround time. In the infant is raised as a boy,
application of topical DHT cream may be a method of assessing
the potential of the genitalia to virilize over the longer term.
XY DSD with normal testosterone, normal precursors
and normal DHT
A defect in androgen signalling is most likely due to dysfunction
of the androgen receptor (AR) and mutations resulting in a
complete lack of function of the AR cause complete androgen
insensitivity syndrome (CAIS).71 This presents in the newborn
infant as a discordance between a female phenotype and a pre-
natal karyotype of 46,XY, as a postnatal check because of a posi-
tive family history or as inguinal swellings in a girl. CAIS usually
presents in adolescence as primary amenorrhoea with normal
breast development. The presence of pubic hair is often reported
in CAIS and should not be used to exclude the diagnosis. Muta-
tions that result in some residual AR function and varying
degrees of androgenization cause partial androgen insensitivity
syndrome (PAIS). Although children with AIS typically have
normal testosterone and DHT response to hCG stimulation and
a normal urinary steroid profile, some demonstrate a poor
response to hCG stimulation.57,72 The serum AMH concentra-
tion is normal or may even be elevated. LH levels are increased
in the face of normal or elevated serum testosterone, reflecting a
state of androgen resistance.55 A family history of X-linked
inheritance is informative although one-third of cases are the
result of spontaneous new mutations.
A functional assessment of androgen sensitivity may include
assessing the clinical effect of a short course of testosterone or
dihydrotestosterone applied on the phallus or by the effect of
systemic testosterone following hCG stimulation. However, there
is no consensus on the choice of androgen, dosage, method of
administration, timing and duration of treatment as well as the
© 2015 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Clinical Endocrinology (2016), 84, 771–788
784 S.F. Ahmed et al.
definition of a satisfactory response in the growth of the phallus.
Androgen sensitivity can be also assessed by measuring change
in sex hormone-binding globulin (SHBG), an androgen-respon-
sive protein that normally decreases following androgen expo-
sure. This fall in SHBG is absent in CAIS, variable in PAIS 73
and difficult to interpret in young infants who have highly vari-
able circulating SHBG. AR analysis may reveal a mutation in
over 90% of cases with a CAIS phenotype, but only 20% of
cases with a PAIS phenotype 74 and androgen receptor-binding
studies are not necessary for routine diagnosis of AIS. A number
of newborns with XY DSD are loosely labelled as ‘PAIS’ when
no conclusive biochemical or genetic abnormalities are identified
in gonadal function, androgen synthesis or androgen action. The
term PAIS should solely be used in the context of a molecular
confirmation of a mutation in AR.
Networks and registers for clinical care, audit and
research
It is unrealistic to expect that every major clinical centre can
possess a comprehensive, multidisciplinary DSD team as out-
lined earlier. Furthermore, in many cases, care at a local hospital
with regular telephone or videolink consultation with the regio-
nal centre may be more appropriate for reasons of both conve-
nience and necessity (for example, adrenal crisis in CAH). For
the less complex case of hypospadias, immediate multidisci-
plinary input may not be necessary and initial discussion and
explanation of the condition with the parents does not require
urgent transfer of the baby at an emotionally sensitive period.
Similarly, some investigations can also be performed at local
centres that are affiliated to a regional centre. It is, however,
important that all personnel who may be involved in the care of
an affected person have access to the regional DSD team and
have the opportunity to develop themselves professionally. Some
regions have overcome these hurdles with the development of a
managed clinical network (www.sdsd.scot.nhs.uk). A service
model such as this ensures the provision of an equitable state-
of-the-art service for all affected children and adolescents in a
region. A formal organization allows a structured referral path-
way within the region as well as beyond and provides the infras-
tructure for better long-term care of the patient as close to
home as possible. A network also facilitates the creation of
nationally agreed protocols for the care of the affected newborn,
setting and monitoring of national standards of care, rational
utilization of other services such as clinical genetics and clinical
biochemistry and provides a forum for education and profes-
sional development.
Research and audit are vital for the management of DSD,
and clinical networks have a strong potential to drive these
activities with the development of care standards including
patient experience data and peer-observation of clinical care
provision. The 2005 Consensus Workshop on DSD stressed the
need for the creation and maintenance of a database in centres
of expertise. Clinical audit systems that collect information on
clinical activity and outcome should be an integral component
of national specialist services. Such databases may exist at a less
formal level in many other regional centres, and until recently
have lacked international uniformity and the ability to cross-
talk. A web-based register has been approved by the UK
National Research Ethics Service as a multicentre research data-
base, which does not require any further local research
approvals but does require the approval of the patient or par-
ent.75 This web-based register, www.I-DSD.org, which was ini-
tially supported by the European Society for Paediatric
Endocrinology and an EUFP7 framework grant is currently
funded by the MRC and has the potential to address many
unanswered questions about long-term outcome in these rare
conditions. Such registers of patients can also facilitate the
development of local circles of patients and parents with similar
conditions who can support each other.
Conclusion
The rationale for investigating a newborn or an adolescent with
a suspected DSD may include the need to determine the sex of
rearing, to anticipate early medical problems, to explain the aeti-
ology to the young person and the parents of an affected new-
born, to support them psychologically in assimilating this
knowledge and, finally, to develop a management plan that leads
to optimal long-term outcome. A rational and empathic
approach that relies on the skills and knowledge of the experts
within the MDT is essential for achieving these goals. An
unequivocal diagnosis confirmed by biochemical and genetic
means remains elusive in many cases of DSD, particularly XY
DSD. The stepwise approach to reaching the final diagnosis
needs to be explained to parents, and the most important goals
of the initial period of assessment should be to support the
affected person and the parents, assign a sex of rearing and
exclude the possibility of any early medical problems.
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